CPAPtalk.com

Anonymous wrote:can't you dopes stick with the topic of this thread? GOD.

That might be asking alot from a bunch of old, opinionated geezers.

Did you have something constructive to contribute?

Den

Anonymous wrote:can't you dopes stick with the topic of this thread? GOD.

While we did get off topic.... I think we are at a critical point in our country and I think any dialog in regards to our country's future is of the utmost importance and much more than the original topic.

Given all the current problems the US is currently facing.... this could well be the most important election in the history of our country.


WE NEED REAL CHANGE IN WASHINGTON!!!!!!!!!!!!!!!!!!

ResMed Inc., the world's second-biggest maker of equipment for breathing-related sleep disorders, surged to an eight-month high on the Australian stock exchange after an analyst said it may be a takeover target.

ResMed is a group that's definitely on the radar at the moment.

ResMed climbed 36 cents, or 6.5 percent, to A$5.88, its highest since April 23. The company could be a takeover target, JPMorgan Chase & Co. analyst Alexander Smith said, after Royal Philips Electronics NV agreed on Dec. 21 to buy the world's largest sleep-apnea device maker, Respironics Inc.

Telephone calls by Bloomberg News to ResMed's investor relations and corporate communications departments weren't answered. A message left on an investor relations officer's mobile-phone voicemail wasn't returned.

Sleep apnea, a disorder that can cause people to briefly stop breathing during sleep, affects as many as 12 million Americans.

Shares of ResMed Inc. rose 9% to $51.20 Friday on the NY stock exchange after its competitor, Respironics Inc., reached an agreement to be acquired by Royal Philips Electronics for a $66 a share, a 24% premium to its closing stock price Thursday.

Both ResMed and Respironics are manufacturers of medical devices used in the treatment of sleep-related respiratory disorders.

"We think investors should play this by buying RMD [Resmed]," Wachovia said in a note to clients, adding that "we believe RMD's scarcity value will increase as it becomes the only sleep company."

Wachovia rated both ResMed and Respironics outperform. It has a $57 price target on ResMed.

The Israeli sleep diagnostic company WideMed Ltd. has reached a deal with Pfizer Inc. sister company Pfizer Ltd. to use the for development of WideMed's Morpheus sleep analytics system. The agreement is for one year or until the completion of the work plan, whichever comes first.

Morpheus is a automated computer aided cardio-sleep information system, which has been approved by the US Food and Drug Administration (FDA). The system provides data on sleep stages, sleep apnea, and other disorders, in order to facilitate the application of appropriate treatments.

Don't you just HATE people that come here and bitch but have nothing constructive to contribute!!

Jerry

It keep them off the Streets If they come here to bother us, they are having to leave someone else alone, after all we hold the door open for them, most sites don't. Jim